- Home
- LBRX vs CERS Comparison
LBRX vs CERS Comparison
Compare LBRX & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBRX
- CERS
- Stock Information
- Founded
- LBRX 2015
- CERS 1991
- Country
- LBRX United States
- CERS United States
- Employees
- LBRX N/A
- CERS N/A
- Industry
- LBRX Biotechnology: Pharmaceutical Preparations
- CERS EDP Services
- Sector
- LBRX Health Care
- CERS Technology
- Exchange
- LBRX Nasdaq
- CERS Nasdaq
- Market Cap
- LBRX 337.7M
- CERS 276.0M
- IPO Year
- LBRX 2025
- CERS 1997
- Fundamental
- Price
- LBRX $16.00
- CERS $1.48
- Analyst Decision
- LBRX Strong Buy
- CERS Buy
- Analyst Count
- LBRX 3
- CERS 1
- Target Price
- LBRX $46.33
- CERS $4.00
- AVG Volume (30 Days)
- LBRX 109.9K
- CERS 1.2M
- Earning Date
- LBRX 11-06-2025
- CERS 11-06-2025
- Dividend Yield
- LBRX N/A
- CERS N/A
- EPS Growth
- LBRX N/A
- CERS N/A
- EPS
- LBRX N/A
- CERS N/A
- Revenue
- LBRX N/A
- CERS $199,191,000.00
- Revenue This Year
- LBRX N/A
- CERS $19.07
- Revenue Next Year
- LBRX N/A
- CERS $12.03
- P/E Ratio
- LBRX N/A
- CERS N/A
- Revenue Growth
- LBRX N/A
- CERS 13.03
- 52 Week Low
- LBRX $13.36
- CERS $1.12
- 52 Week High
- LBRX $20.25
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- LBRX N/A
- CERS 46.55
- Support Level
- LBRX N/A
- CERS $1.38
- Resistance Level
- LBRX N/A
- CERS $1.78
- Average True Range (ATR)
- LBRX 0.00
- CERS 0.11
- MACD
- LBRX 0.00
- CERS -0.01
- Stochastic Oscillator
- LBRX 0.00
- CERS 26.25
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.